Background: Frontotemporal dementia (FTD) is characterized by progressive deterioration in behaviors, executive function and/or language. The behavioral variant (Bv) is characterized by disinhibition and obsessive/compulsive behaviors. These symptoms are sometimes resistant to medications. This series examines patients suffering with treatment-resistant Bv-FTD who were prescribed cannabinoid and related compounds for other indications. Case presentation: Three FTD cases from a dementia clinic were identified. These patients had disability due to behavior despite typical pharmacologic management. These patients were prescribed marijuana for comorbidities (anxiety, insomnia and pain). In all cases, use of cannabinoid products showed significant improvements in behavior and in the primary indication for prescription. Conclusion: Review of these cases demonstrates potential for the use of cannabinoids in the management of treatment-resistant Bv-FTD.
Keywords: CBD; FTD; behavioral variant FTD; cannabinoids; dementia; frontotemporal dementia; medical marijuana; tetrahydrocannabinol.
Frontotemporal degeneration (FTD) is a group of rare conditions that can affect a person’s behavior and ability to move or speak. Together, they are the most common cause of dementia in people under the age of 60.
Association For Frontotemporal DeGeneration
National Aphasia Association (NAA) is a nonprofit organization that promotes public awareness and understanding of aphasia. It also offers support for affected people and their caregivers. Visit the NAA’s website to access:
National Aphasia Association
CurePSP is an advocacy organization working to improve awareness, education, and care for prime of life neurodegenerative diseases. Its website has many resources, including: